Document Detail


Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women.
MedLine Citation:
PMID:  15284085     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Previous studies indicated that oral estrogen increased C-reactive protein by a first-pass hepatic effect. In this study, we determine whether the route of estrogen administration influences serum amyloid A (SAA), another acute-phase protein produced by the liver, and the SAA content of the high-density lipoprotein (HDL-SAA) in postmenopausal women. METHODS AND RESULTS: In 29 postmenopausal women without coronary heart disease, we conducted a randomized crossover placebo-controlled study to compare effects of transdermal versus oral estrogen on SAA and HDL-SAA. SAA, apolipoprotein A-I, HDL, and HDL-SAA were measured before and after 8 weeks of transdermal estradiol (100 microg per day), oral-conjugated estrogens (0.625 mg per day), or placebo. We found that oral estrogen significantly increased levels of SAA, HDL, and HDL-SAA, whereas transdermal estrogen reduced both SAA and HDL-SAA but had no effect on HDL in the same women. CONCLUSIONS: Oral estrogen increased SAA and altered HDL composition to contain a higher level of SAA by a first-pass hepatic mechanism. Because elevated SAA levels predict adverse prognosis in healthy postmenopausal women, and elevated HDL-SAA levels have been shown to interfere with HDL function, the route of administration may be an important consideration in minimizing side effects of estrogen replacement therapy on cardiovascular outcomes.
Authors:
Aamer Abbas; Paul J Fadel; Zhongyun Wang; Debbie Arbique; Ishwarlal Jialal; Wanpen Vongpatanasin
Related Documents :
8458645 - Estrogen receptor variant and hypertension in women.
18779755 - Prevalence of symptoms in relation to androgen concentrations in women using estrogen p...
9193885 - The pathophysiology and treatment of postmenopausal osteoporosis. an evidence-based app...
18955645 - Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-...
19783595 - The effect of the world kidney day campaign on the awareness of chronic kidney disease ...
1878625 - Symptoms and correlates of anabolic-androgenic steroid dependence.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2004-07-29
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  24     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-08     Completed Date:  2005-03-24     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e164-7     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, University of Texas, Dallas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Administration, Oral
Cross-Over Studies
Estrogens / administration & dosage*,  pharmacology*
Female
Humans
Lipoproteins, HDL / blood*
Middle Aged
Postmenopause / physiology*
Serum Amyloid A Protein / metabolism*
Grant Support
ID/Acronym/Agency:
K23RR16321/RR/NCRR NIH HHS; K24AT00596/AT/NCCAM NIH HHS; M01-RR00633/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Estrogens; 0/Lipoproteins, HDL; 0/Serum Amyloid A Protein
Comments/Corrections
Comment In:
Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1741-2   [PMID:  15472134 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  System beta and system A amino acid transporters in the feline endotheliochorial placenta.
Next Document:  Can exercise training with weight loss lower serum C-reactive protein levels?